Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Abbott and Wyeth to Develop Test for Sirolimus

By HospiMedica staff writers
Posted on 28 Dec 2003
A collaboration to jointly develop an automated blood test to monitor therapeutic levels of sirolimus, an anti-rejection drug for transplant patients, has been announced by Abbott Laboratories (Abbott Park, IL, USA) and (Madison, NJ, USA). More...


Under the agreement, the two companies will develop the test for use on Abbott's Imx and other automated immunoassay systems. The test will be manufactured by Axis-Shield plc (Dundee, Scotland), and Abbott will distribute it worldwide. Abbott now provides tests to monitor the immunosuppressant drugs cyclosporine and tacrolimus. A lifelong regimen of immunosuppressant drugs is given to transplant patients to lower the body's normal immune response and allow the transplanted organ to remain functional. Sirolimus is recommended for the prophylaxis of organ rejection in patients receiving a renal transplant.

"Our agreement with Wyeth builds upon our leadership position in transplant diagnostics and reinforces our commitment to improve the medical outcome for patients who have undergone kidney transplants,” said William Brown, Ph.D., vice president, diagnostic assays and systems development, Abbott Laboratories.




Related Links:
Abbott
Wyeth

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Pediatric Mask
Respire SOFT
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.